pharma · Chronic kidney disease · Advanced solid tumors
Bayer
Bayer AG
Bayer clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
- Employees
- 97,894
- Programs
- 47
- Drugs
- 62
- Patents
- 5
Bayer projects
8 ClinicalTrials.gov programs sponsored by Bayer.
Bayer has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
19920
Bayer AG
Proteinuria, Chronic kidney disease
1 trial -
20186
Bayer AG
Treatment of children with chronic kidney disease and proteinuria
1 trial -
21177
Bayer AG
Non-diabetic chronic kidney disease
1 trial -
21466
Bayer AG
Heart failure due to systemic left ventricular systolic dysfunction
1 trial -
21467
Bayer AG
Heart failure due to systemic left ventricular systolic dysfunction
1 trial -
22615
Bayer AG
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
1 trial -
BAY 3427080, BAY 3427080 60 mg capsules placebo
Bayer AG
Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer
1 trial -
BAY 94-9027/21824
Bayer AG
Severe hemophilia A (<1% FVIII:C)
1 trial
Frequently asked questions
How many clinical projects does Bayer have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.